Polivy
Polivy Approved for Previously Untreated DLBCL, Not Otherwise Specified, or High-Grade B-Cell Lymphoma
The FDA approved polatuzumab vedotin-piiq (Polivy, Genentech) with R-CHP (rituximab, cyclophosphamide, doxorubicin, ...
APRIL 21, 2023
Large Study Suggests Possible New Standard for Previously Treated DLBCL
A new drug regimen containing the antibody-drug conjugate polatuzumab vedotin-piiq is challenging the previous ...
FEBRUARY 11, 2022
Load more